Selecta Biosciences falls on Q2 revenue miss

Cartesian Therapeutics

17/08/2023 14:59

** Shares of drug developer Selecta Biosciences  SELB.O 
fall 1.8% to $1
    ** Co reports Q2 revenue of $5.2 mln vs analysts' estimate
of $6.8 mln according to Refinitiv data
    ** SELB says it plans to suspend further investment in other
therapy developments and focus on advancing its gout treatment
    ** Including session losses, shares down 6.2% YTD

 (Reporting by Christy Santhosh in Bengaluru)
 ((Christy.Santhosh@thomsonreuters.com))